Atrial fibrillation clinical trials, in English

This is a single-center prospective watch-and-measure (no experimental treatment required) cohort study of atrial fibrillation patients treated with radiofrequency ablation.

NCT05266144 · Official ClinicalTrials.gov record · Peking Union Medical College Hospital

Background: Bruton s tyrosine kinase inhibitors (BTKi) are used to treat a form of leukemia. But taking BTKi can also increase a person s risk of developing an abnormal heart rhythm.

NCT05724121 · Official ClinicalTrials.gov record · National Heart, Lung, and Blood Institute (NHLBI)

REACT-AF is a multicenter prospective, randomly assigned, open-label, blinded endpoint (PROBE design), controlled trial comparing the current Standard Of Care (SOC) of continuous Direct Oral Anticoagulation (DOAC) use versus time-delimited (1 month) DOAC guided by an AF-sensing Smart Watch (AFSW) in participants with a history of paroxysmal or persistent Atrial Fibrillation (AF) and low-to-moderate stroke risk.

NCT05836987 · Official ClinicalTrials.gov record · Johns Hopkins University

Atrial fibrillation (AF) is one of the most common cardiac arrhythmias and cardioembolic stroke due to AF is its major complication. Direct oral anticoagulants (DOAC) reduce the risk of cardioembolism in patients with AF.

NCT05976685 · Official ClinicalTrials.gov record · Insel Gruppe AG, University Hospital Bern

This study is to look at the success of Intracardiac Echocardiography (ICE) in the Watchman procedure. Currently the process is to use a Transesophageal Echocardiography (TEE) to place the Watchman in patients.

NCT06007872 · Official ClinicalTrials.gov record · The Cleveland Clinic

Atrial fibrillation is a cardiac arrhythmia most often originating in the left atrium, causing anarchic electrical activity and thus a loss of atrial contraction. This increases the risk of stroke through clot formation in the atrium, but also of heart failure.

NCT06047782 · Official ClinicalTrials.gov record · Centre Hospitalier Universitaire Dijon

Recurrent focal electrical activation (or ectopy) superseding sinus activation is the only mechanism proven to drive paroxysmal atrial fibrillation (AF). However, it has not been possible to show similar focal drivers during AF, owing to the limitations of mapping in persistent AF.

NCT06402617 · Official ClinicalTrials.gov record · Imperial College London

PULSED AF PAS is a prospective, global, multi-center, non-randomly assigned, watch-and-measure (no experimental treatment required) trial. Subjects will be treated with the PulseSelect™ PFA System and followed through 36 months.

NCT06578104 · Official ClinicalTrials.gov record · Medtronic Cardiac Ablation Solutions

This study looks at whether stroke patients who take FXa inhibitors (a type of blood thinner) can safely receive clot-busting treatment (IVT). IVT is a common emergency treatment for stroke, but current guidelines say it should not be given to people who have taken FXa inhibitors in the last 48 hours.

NCT06878066 · Official ClinicalTrials.gov record · Guri Hagberg

The goal of this watch-and-measure (no experimental treatment required) study is to better understand the role of measuring troponin (a protein measured by a blood test) and coronary imaging in patients presenting with rapid atrial fibrillation (AF) The main questions this study aims to answer are: 1. Are patients with a fast, irregular heartbeat (rapid AF) and damage to the heart (myocardial injury) more likely than those without damage to the heart to have blocked heart arteries (obstructive coronary artery disease) 2.

NCT06951100 · Official ClinicalTrials.gov record · University of Edinburgh

This study wants to assess the safety and feasibility of the investigational catheter for mapping the atrial and ventricular regions of the heart.

NCT07116525 · Official ClinicalTrials.gov record · Biosense Webster, Inc.

This study is researching experimental drugs called REGN7508 and REGN9933. The study is focused on participants who have atrial fibrillation, which means that the heart beats too fast and unevenly.

NCT07175428 · Official ClinicalTrials.gov record · Regeneron Pharmaceuticals

The objective of the study is to collect data on the use of the VERAFEYE Anatomical Guidance System in adult patients indicated to undergo a catheter ablation procedure for the treatment of Atrial Flutter (AFL), paroxysmal AF (PAF) or persistent AF (perAF). The study will collect specific information on management of AFL/AF ablation procedures with the commercial VERAFEYE Anatomical Guidance System including but not limited to acute procedural success , and how the VERAFEYE Anatomical Guidance System is used overall.

NCT07210151 · Official ClinicalTrials.gov record · LUMA Vision Ltd.

A randomly assigned, compared with a dummy treatment, participant-and investigator-blinded study to measure the how well it works in reducing atrial fibrillation burden as well as the safety, tolerability and pharmacokinetics of PKN605 in participants with atrial fibrillation

NCT07217067 · Official ClinicalTrials.gov record · Novartis Pharmaceuticals

This study wants to measure the long-term safety and effectiveness of the FDA approved VARIPULSE catheter system for pulmonary vein isolation (PVI) in the treatment of participants with symptomatic paroxysmal atrial fibrillation (PAF).

NCT07227532 · Official ClinicalTrials.gov record · Biosense Webster, Inc.

The objective of the study is to collect data on the usability and integration of the VERAFEYE Imaging and Guidance System in adult patients indicated to undergo a standard of care catheter-based ablation procedure for the treatment of Atrial Flutter (AFL), paroxysmal AF (PAF) or persistent AF (perAF). Results from this study may be used to guide development and refinement the VERAFEYE Imaging and Guidance System capabilities.

NCT07271238 · Official ClinicalTrials.gov record · LUMA Vision Ltd.

The OPTION-EMEA post-market study is intended to gather real world clinical data for patients undergoing AF ablation with the FARAPULSE™ Pulsed Field Ablation (PFA) System and subsequent left atrial appendage closure (LAAC) with a WATCHMAN FLX™ Pro or WATCHMAN FLX device during one treatment case. The study will include patients that are clinically indicated for atrial fibrillation (AF) ablation using the FARAPULSE PFA System and for left atrial appendage closure (LAAC) treatment using a WATCHMAN FLX Pro or WATCHMAN FLX device as part of the patient's standard of care determined by their doctor's medical judgement.

NCT07349121 · Official ClinicalTrials.gov record · Boston Scientific Corporation

This study is researching 2 different experimental drugs called REGN7508 and REGN9933 (called "study drugs"). The study is focused on people who have atrial fibrillation, which means that the heart beats too fast and unevenly.

NCT07430956 · Official ClinicalTrials.gov record · Regeneron Pharmaceuticals

The goal of this randomly assigned clinical trial is to evaluate whether a peer-mentor intervention can improve mental well-being among vulnerable patients with atrial fibrillation (AF). Patients with AF often experience anxiety, uncertainty, and reduced quality of life.

NCT07498283 · Official ClinicalTrials.gov record · University College Copenhagen

The main purpose of the study is to assess how well the standard ablation procedure (Varipulse Catheter) works over long term when used with different types of anesthesia in participants with symptomatic paroxysmal atrial fibrillation (PAF, irregular heartbeat that comes and goes on its own, causing noticeable symptoms like a racing heart, or shortness of breath).

NCT07511166 · Official ClinicalTrials.gov record · Johnson & Johnson Medical (Shanghai) Ltd.

This study wants to assess how safe VARIPULSE pulsed field ablation (PFA) catheter is and how well it works compared to food and drug administration (FDA) approved FARAWAVE PFA catheter in participants with symptomatic persistent atrial fibrillation (PsAF; continuous irregular, rapid heartbeat that lasts over 7 days and doesn't stop on its own).

NCT07523750 · Official ClinicalTrials.gov record · Biosense Webster, Inc.

This study wants to assess how safe VARIPULSE catheter system is for treatment of a heart rhythm disease called persistent atrial fibrillation (PsAF) in participants who are having a catheter ablation procedure (treat heart rhythm disease). This includes isolation of pulmonary vein and superior vena cava (heart veins; pulmonary vein isolation \[PVI\] and superior vena cava isolation \[SVCI\]), with or without another technique called posterior wall isolation (PWI).

NCT07527299 · Official ClinicalTrials.gov record · Biosense Webster, Inc.

This study is researching an experimental drug called REGN7508 (called "study drug") and how it compares against another treatment called apixaban. The study is focused on people who have atrial fibrillation, which means that the heart beats too fast and unevenly.

NCT07626411 · Official ClinicalTrials.gov record · Regeneron Pharmaceuticals

Trial fibrillation (AF) is the most common cardiac arrhythmia worldwide, and its prevalence continues to rise. AF is associated with serious complications, including embolic strokes, heart failure, and mortality.

NCT07648329 · Official ClinicalTrials.gov record · Centre Hospitalier Universitaire Dijon

This post-market registry is designed to collect real world data on the use of the Globe PF System for the treatment of atrial fibrillation (AF).

NCT07651852 · Official ClinicalTrials.gov record · Kardium Inc.

The DISRUPT-AF Registry is an watch-and-measure (no experimental treatment required), prospective, multi-center, non-randomly assigned, real-world registry designed to obtain clinical experience with the FARAPULSE Pulsed Field Ablation (PFA) System for the treatment of atrial fibrillation (AF). The data collected for this study will be from a subset of patients enrolled in the pre-existing DISRUPT AF Registry.

NCT07671677 · Official ClinicalTrials.gov record · Heart Rhythm Clinical and Research Solutions, LLC

SGLT2 inhibitors improve outcomes in heart failure across the ejection fraction spectrum, but their effect on maintenance of sinus rhythm after rhythm-control therapy is largely unknown. This prospective, single-center, open-label randomly assigned controlled trial evaluates whether an SGLT2 inhibitor started after successful electrical cardioversion reduces recurrence of atrial tachyarrhythmia at 1 month in patients with persistent atrial fibrillation and heart failure with preserved ejection fraction.

NCT07776054 · Official ClinicalTrials.gov record · Samsung Medical Center

This pilot study is designed to measure the clinical performance and utility of the SmartECG-EF software in patients undergoing evaluations at Inha University Hospital. The primary objective is to assess how effectively the device assists clinicians in evaluating cardiac function and related clinical parameters.

NCT07844434 · Official ClinicalTrials.gov record · Inha University Hospital

This purpose of this study is to understand how safe Biosense Webster Pulsed Field (PF)/Radiofrequency (RF) ablation system is and how well it works over 12 months in participants with persistent atrial fibrillation (PsAF; abnormal heart signals that cause irregular heartbeats).

NCT07845682 · Official ClinicalTrials.gov record · Biosense Webster, Inc.

This prospective, multicenter, randomly assigned, controlled, noninferiority trial will compare local anesthesia with conscious sedation and general anesthesia in patients undergoing pulsed field ablation for paroxysmal atrial fibrillation. A total of 390 participants aged 18 to 80 years will be randomly assigned in a 1:1 ratio to undergo pulsed field ablation under either local anesthesia with conscious sedation or general anesthesia.

NCT07877519 · Official ClinicalTrials.gov record · China National Center for Cardiovascular Diseases

Pulsed Field Ablation (PFA) has created a 'paradigm shift' within cardiac electrophysiology and the initial experience demonstrates that PFA is safe, rapid and effective compared to both radiofrequency ablation and cryoablation in atrial fibrillation (AF). Presently, AF ablation procedures in the UK using PFA are routinely performed using general anaesthetic (GA) support requiring an anaesthetist and ODP being present in all procedures.

NCT07900685 · Official ClinicalTrials.gov record · East Sussex Healthcare NHS Trust

The STREAMLINE-PVI trial is a prospective, single-center, randomly assigned, open-label clinical trial comparing pulsed field ablation (PFA) with cryoballoon ablation (Cryo) for pulmonary vein isolation (PVI) in patients with atrial fibrillation (AF). A total of 94 patients undergoing first-time PVI will be randomly assigned 1:1 to either PFA or Cryo within standardized Lean Six Sigma (LSS)-optimized procedural workflows.

NCT07910370 · Official ClinicalTrials.gov record · St. Josefs-Hospital Wiesbaden GmbH

Heart failure with preserved ejection fraction (HFpEF) is characterized by typical symptoms of heart failure, structural and functional cardiac abnormalities, and elevated serum levels of N-terminal pro-B-type natriuretic peptide (NT-proBNP), despite preserved left ventricular ejection fraction. Typical symptoms of HFpEF include reduced exercise tolerance, exertional dyspnea, paroxysmal nocturnal dyspnea, and orthopnea.

NCT07918209 · Official ClinicalTrials.gov record · American Heart of Poland

Stroke is a leading cause of death and adult disability. Stroke care is still limited by fragmented care pathways, non-standardised diagnostic work-up and follow-up, and local, non-interoperable data systems across the pre-hospital, in-hospital and post-hospital settings.

NCT07924371 · Official ClinicalTrials.gov record · Hospital Universitari Vall d'Hebron Research Institute